Which product is indicated as an injectable for 30-day pain management in arthritic canines?

Librela is an injectable medication specifically indicated for pain management in dogs suffering from osteoarthritis. It contains the active ingredient bedinvetmab, which is a monoclonal antibody that targets nerve growth factor (NGF) involved in the pain signaling pathway. By inhibiting NGF, Librela effectively reduces pain and improves the quality of life for arthritic canines.

The formulation is designed for long-lasting effects, requiring only monthly administration, which makes it a convenient option for pet owners as it simplifies the pain management regimen. This targeted approach is particularly beneficial for dogs with chronic conditions like arthritis, where ongoing pain management is crucial.

The other options, while relevant in various contexts (e.g., Dasuquin for joint health support or ProHeart for heartworm prevention), do not directly address the specific need for injectable pain management in arthritic dogs over a 30-day period. Therefore, Librela is the preferred choice for this purpose due to its specific formulation and duration of action.